{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:11:37Z","timestamp":1785435097123,"version":"3.56.0"},"reference-count":105,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>By the end of 2022, different variants of Omicron had rapidly spread worldwide, causing a significant impact on the Coronavirus disease 2019 (COVID-19) pandemic situation. Compared with previous variants of severe acute respiratory syndrome coronavirus 2 (SARS\u2013CoV-2), these new variants of Omicron exhibited a noticeable degree of mutation. The currently developed platforms to design COVID-19 vaccines include inactivated vaccines, mRNA vaccines, DNA vaccines, recombinant protein vaccines, virus-like particle vaccines, and viral vector vaccines. Many of these platforms have obtained approval from the US Food and Drug Administration (FDA) or the WHO. However, the Omicron variants have spread in countries where vaccination has taken place; therefore, the number of cases has rapidly increased, causing concerns about the effectiveness of these vaccines. This article first discusses the epidemiological trends of the Omicron variant and reviews the latest research progress on available vaccines. Additionally, we discuss progress in the development progress and practical significance of universal vaccines. Next, we analyze the neutralizing antibody effectiveness of approved vaccines against different variants of Omicron, heterologous vaccination, and the effectiveness of multivalent vaccines in preclinical trials. We hope that this review will provide a theoretical basis for the design, development, production, and vaccination strategies of novel coronavirus vaccines, thus helping to end the SARS-CoV-2 pandemic.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1294288","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T06:54:35Z","timestamp":1701068075000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Analysis of the protective efficacy of approved COVID-19 vaccines against Omicron variants and the prospects for universal vaccines"],"prefix":"10.3389","volume":"14","author":[{"given":"Keda","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongbiao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaonan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wancheng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2020.03.036","article-title":"Coronavirus Disease (COVID-19): A primer for emergency physicians","volume":"44","author":"Chavez","year":"2021","journal-title":"Am J Emerg Med"},{"key":"B2","unstructured":"Coronavirus disease (COVID-19) \u2013 World Health Organization"},{"key":"B3","unstructured":"WHO coronavirus (COVID-19) dashboard"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm1208","article-title":"Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness","volume":"376","author":"Obermeyer","year":"2022","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032264","article-title":"Convergent evolution in SARS-coV-2 spike creates a variant soup from which new COVID-19 waves emerge","volume":"24","author":"Focosi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/v14061239","article-title":"Recombination in coronaviruses, with a focus on SARS-coV-2","volume":"14","author":"Focosi","year":"2022","journal-title":"Viruses"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01882-4","article-title":"Drivers of adaptive evolution during chronic SARS-CoV-2 infections","volume":"28","author":"Harari","year":"2022","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"n1088","DOI":"10.1136\/bmj.n1088","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study","volume":"373","author":"Lopez Bernal","year":"2021","journal-title":"BMJ"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01454-y","article-title":"COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries","volume":"27","author":"Sol\u00eds Arce","year":"2021","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00212-5","article-title":"The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study","volume":"3","author":"Mahil","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.08.066","article-title":"Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness","volume":"35","author":"Wichmann","year":"2017","journal-title":"Vaccine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2008.11.006","article-title":"Influenza vaccines: The virosome concept","volume":"122","author":"Wilschut","year":"2009","journal-title":"Immunol Lett"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30773-8","article-title":"What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2","volume":"21","author":"Hodgson","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11010075","article-title":"A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19 Pandemic in Poland-Evaluation of Antibody Concentrations","volume":"11","author":"Zapolnik","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.804945","article-title":"Analysis of the protective efficacy of approved COVID-19 vaccines against various mutants","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05644-7","article-title":"Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution","volume":"614","author":"Cao","year":"2023","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6927","DOI":"10.1038\/s41598-021-86380-2","article-title":"In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2","volume":"11","author":"Jafary","year":"2021","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/path.5471","article-title":"Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)","volume":"251","author":"Bourgonje","year":"2020","journal-title":"J Pathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41392-023-01391-x","article-title":"Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2","volume":"8","author":"Zhu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05053-w","article-title":"Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5","volume":"608","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00070-1","article-title":"Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate","volume":"23","author":"Uraki","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00278-5","article-title":"Genotype to Phenotype Japan (G2P-Japan) Consortium, Ito J, Sato K. Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant","volume":"23","author":"Yamasoba","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04980-y","article-title":"BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection - PubMed","volume":"608","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41392-022-00941-z","article-title":"SARS-CoV-2 spike L452R mutation increases Omicron variant fusogenicity and infectivity as well as host glycolysis","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1101\/2022.10.19.512891","article-title":"Distinct neutralizing antibody escape of SARS-coV-2 omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2","volume":"2022","author":"Qu","year":"2022","journal-title":"bioRxiv"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015477","article-title":"Efficacy and safety of COVID-19 vaccines","volume":"2022","author":"Gra\u00f1a","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"B28","article-title":"DNA vaccines\u2013challenges in delivery","volume":"2","author":"Pachuk","year":"2000","journal-title":"Curr Opin Mol Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.3390\/ijms21186582","article-title":"mRNA vaccine era\u2014Mechanisms, drug platform and clinical prospection","volume":"21","author":"Xu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2019.10.002","article-title":"Tailoring mRNA vaccine to balance innate\/adaptive immune response","volume":"26","author":"Linares-Fern\u00e1ndez","year":"2020","journal-title":"Trends Mol Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200674","article-title":"Safety and efficacy of a third dose of BNT162b2 covid-19 vaccine","volume":"386","author":"Moreira","year":"2022","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02092-8","article-title":"Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice","volume":"29","author":"Scheaffer","year":"2023","journal-title":"Nat Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2214293","article-title":"Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster","volume":"388","author":"Davis-Gardner","year":"2023","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7144a3","article-title":"Safety monitoring of bivalent COVID-19 mRNA vaccine booster doses among persons aged \u226512 years - United States, august 31-october 23, 2022","volume":"71","author":"Hause","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1586\/erv.09.43","article-title":"SARS vaccines: where are we","volume":"8","author":"Roper","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"B36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-023-01352-8","article-title":"Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters","volume":"8","author":"Nouailles","year":"2023","journal-title":"Nat Microbiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41562-021-01160-2","article-title":"Author Correction: A global database of COVID-19 vaccinations","volume":"5","author":"Mathieu","year":"2021","journal-title":"Nat Hum Behav"},{"key":"B40","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41392-020-00352-y","article-title":"A systematic review of SARS-CoV-2 vaccine candidates","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-023-01352-8","article-title":"A non-transmissible live attenuated SARS-CoV-2 vaccine","volume":"8","author":"Adler","year":"2023","journal-title":"Nat Microbiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00095-2","article-title":"Boosting immunity after CoronaVac","volume":"399","author":"Sester","year":"2022","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1038\/s41467-022-31930-z","article-title":"A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00345-0","article-title":"Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study","volume":"22","author":"McMenamin","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1032411","article-title":"Humoral and cellular immune responses to CoronaVac up to one year after vaccination","volume":"13","author":"Costa","year":"2022","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2014","article-title":"Influenza vaccine: Where are we and where do we go","volume":"29","author":"Keshavarz","year":"2019","journal-title":"Rev Med Virol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41467-023-36250-4","article-title":"SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection","volume":"14","author":"Pu\u0161nik","year":"2023","journal-title":"Nat Commun"},{"key":"B48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00730-8","article-title":"SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients","volume":"18","author":"Deng","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10111804","article-title":"Sputnik Light and Sputnik V Vaccination Is Effective at Protecting Medical Personnel from COVID-19 during the Period of Delta Variant Dominance","volume":"10","author":"Sukhikh","year":"2022","journal-title":"Vaccines"},{"key":"B53","unstructured":"The CanSino Biologics Ad5-nCoV-S [recombinant] COVID-19 vaccine: What you need to know"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00350-X","article-title":"Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial","volume":"23","author":"Li","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2155251","DOI":"10.1080\/22221751.2022.2155251","article-title":"Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial","volume":"12","author":"Jin","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00049-8","article-title":"Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial","volume":"11","author":"Tang","year":"2023","journal-title":"Lancet Respir Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1038\/s41467-023-37697-1","article-title":"An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters","volume":"14","author":"Deng","year":"2023","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41392-022-00996-y","article-title":"COVID-19 vaccine development: milestones, lessons and prospects","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B59","doi-asserted-by":"publisher","first-page":"66","DOI":"10.24875\/BMHIM.20000217","article-title":"Development of SARS-coV-2 vaccines","volume":"78","author":"Barajas-Nava","year":"2021","journal-title":"Bol Med Hosp Infant Mex"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/s41598-023-27698-x","article-title":"Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages","volume":"13","author":"Bhiman","year":"2023","journal-title":"Sci Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2216233","article-title":"Neutralization of BQ.1, BQ.1.1, and XBB with RBD-dimer vaccines","volume":"388","author":"Li","year":"2023","journal-title":"N Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.18.1.927","article-title":"DNA vaccines: immunology, application, and optimization*","volume":"18","author":"Gurunathan","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101020","article-title":"Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I\/II clinical study by intradermal route in healthy subjects in India","volume":"38","author":"Momin","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B64","unstructured":"Zydus cadila: zyCoV-D \u2013 COVID19 vaccine tracker"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00151-9","article-title":"Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India","volume":"399","author":"Khobragade","year":"2022","journal-title":"Lancet"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2004.09.009","article-title":"Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system","volume":"576","author":"Mortola","year":"2004","journal-title":"FEBS Lett"},{"key":"B67","unstructured":"Medicago Covifenz COVID-19 vaccine - Canada.ca"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201300","article-title":"Efficacy and safety of a recombinant plant-based adjuvanted covid-19 vaccine","volume":"386","author":"Hager","year":"2022","journal-title":"N Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2213907","article-title":"Antibody response to omicron BA.4\u2013BA.5 bivalent booster","volume":"388","author":"Wang","year":"2023","journal-title":"New Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2213948","article-title":"Immunogenicity of BA.5 bivalent mRNA vaccine boosters","volume":"388","author":"Collier","year":"2023","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1056\/NEJMc2301323","article-title":"Bivalent covid-19 vaccines","volume":"388","author":"Marks","year":"2023","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm715152e1","article-title":"Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION network, nine states, september-november 2022","volume":"71","author":"Tenforde","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00132-9","article-title":"Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1","volume":"23","author":"Uraki","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg9857","article-title":"Scent of a vaccine","volume":"373","author":"Lund","year":"2021","journal-title":"Science"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abb6808","article-title":"T resident helper cells promote humoral responses in the lung","volume":"6","author":"Swarnalekha","year":"2021","journal-title":"Sci Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081309","article-title":"Inhalable vaccines: can they help control pandemics","volume":"10","author":"Chavda","year":"2022","journal-title":"Vaccines"},{"key":"B77","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1038\/s41467-023-39766-x","article-title":"Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men","volume":"14","author":"Hannawi","year":"2023","journal-title":"Nat Commun"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-022-2207-7","article-title":"A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants","volume":"66","author":"Wang","year":"2023","journal-title":"Sci China Life Sci"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.04.007","article-title":"The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection","volume":"186","author":"Arieta","year":"2023","journal-title":"Cell"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo3332","article-title":"Vaccination with Span, an antigen guided by SARS-CoV-2 S protein evolution, protects against challenge with viral variants in mice","volume":"15","author":"Zhao","year":"2023","journal-title":"Sci Transl Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01911-2","article-title":"Emergence of SARS-coV-2 omicron lineages BA.4 and BA.5 in South Africa","volume":"28","author":"Tegally","year":"2022","journal-title":"Nat Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1038\/s41467-023-40033-2","article-title":"Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters","volume":"14","author":"Machado","year":"2023","journal-title":"Nat Commun"},{"key":"B83","doi-asserted-by":"publisher","first-page":"100762","DOI":"10.1016\/j.lanwpc.2023.100762","article-title":"Heterologous inactivated virus\/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1","volume":"33","author":"Zuo","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"B84","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41421-023-005","article-title":"Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by breakthrough infection sera from previous and recent waves in China","volume":"9","author":"Wang","year":"2023","journal-title":"Cell Discov"},{"key":"B85","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","article-title":"BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection","volume":"608","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7142a3","article-title":"Effectiveness of monovalent mRNA vaccines against COVID-19\u2013associated hospitalization among immunocompetent adults during BA.1\/BA.2 and BA.4\/BA.5 predominant periods of SARS-coV-2 omicron variant in the United States \u2014 IVY network, 18 states, december 26, 2021\u2013august 31, 2022","volume":"71","author":"Surie","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00816-7","article-title":"Humoral immuneevasion of the omicronsubvariants BQ.1.1 andXBB - Search Results","volume":"23","author":"Uraki","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2214314","article-title":"Substantial neutralization escape by SARS-coV-2 omicron variants BQ.1.1 and XBB.1","volume":"388","author":"Miller","year":"2023","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"E123","DOI":"10.1002\/ajh.26887","article-title":"XBB.1.5 neutralizing antibodies upon bivalent COVID-19 vaccination are similar to XBB but lower than BQ.1.1","volume":"98","author":"Devasundaram","year":"2023","journal-title":"Am J Hematol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02162-x","article-title":"Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster","volume":"29","author":"Kurhade","year":"2023","journal-title":"Nat Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2214916","article-title":"Neutralization of BA.4\u2013BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine","volume":"388","author":"Zou","year":"2023","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41541-023-00693-z","article-title":"Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants","volume":"8","author":"Lyke","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2023.04.007","article-title":"Clinical virology and effect of Covid-19 vaccination and monoclonal antibodies against highly infectious SARS- CoV-2 omicron sub variant BF.7 (BA.5.2.1.7): A systematic review","volume":"584","author":"Chenchula","year":"2023","journal-title":"Virology"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2022.11.012","article-title":"Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2","volume":"31","author":"Qu","year":"2023","journal-title":"Cell Host Microbe"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fviro.2022.1077155","article-title":"Renewed global threat by the novel SARS-CoV-2 variants \u2018XBB, BF.7, BQ.1, BA.2.75, BA.4.6\u2019: A discussion","volume":"2","author":"Mohapatra","year":"2022","journal-title":"Front Virol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-01030-z","article-title":"Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineage","volume":"20","author":"Nehlmeier","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41392-023-01495-4","article-title":"Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B98","unstructured":"Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination"},{"key":"B99","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41392-023-01447-y","article-title":"Neutralization of Omicron BA.1, BA.5.1.6, BQ.1.3 and XBB1.1 induced by heterologous vaccination Ad5-nCoV and mRNA-1273","volume":"8","author":"Hern\u00e1ndez","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1101\/2022.12.25.521784","article-title":"A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates","author":"Weidenbacher","year":"2022","journal-title":"bioRxiv [Preprint]"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.11.069","article-title":"Nanoparticle vaccines","volume":"32","author":"Zhao","year":"2014","journal-title":"Vaccine"},{"key":"B102","unstructured":"Immunological basis for enhanced immunity of nanoparticle vaccines"},{"key":"B103","unstructured":"Rational design of an epstein-barr virus vaccine targeting the receptor-binding site"},{"key":"B104","unstructured":"Challenges and developments in universal vaccine design against SARS-CoV-2 variants"},{"key":"B105","unstructured":"Influenza and universal vaccine research in China"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1294288\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T06:54:42Z","timestamp":1701068082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1294288\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":105,"alternative-id":["10.3389\/fimmu.2023.1294288"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1294288","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"article-number":"1294288"}}